Literature DB >> 12440368

Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole.

Gwen Schwartz1, Michael G Fehlings.   

Abstract

Traumatic spinal cord injury is a consequence of a primary mechanical insult and a sequence of progressive secondary pathophysiological events that confound efforts to mitigate neurological deficits. Pharmacotherapy aimed at reducing the secondary injury is limited by a narrow therapeutic window. Thus, novel drug strategies must target early pathological mechanisms in order to realize the promise of efficacy for this form of neurotrauma. Research has shown that an accumulation of intracellular sodium as a result of trauma-induced perturbation of voltage-sensitive sodium channel activity is a key early mechanism in the secondary injury cascade. As such, voltage-sensitive sodium channels are an important therapeutic target for the treatment of spinal cord trauma. This review describes the evolution of acute spinal cord injury and provides a rationale for the clinical utility of sodium channel blockers, particularly riluzole, in the management of spinal cord trauma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12440368     DOI: 10.1016/s0079-6123(02)37016-x

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  32 in total

1.  Increased survival and reinnervation of cervical motoneurons by riluzole after avulsion of the C7 ventral root.

Authors:  Sándor Pintér; Balázs Gloviczki; András Szabó; Gábor Márton; Antal Nógrádi
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

Review 2.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 3.  The Role of Intracellular Sodium in the Regulation of NMDA-Receptor-Mediated Channel Activity and Toxicity.

Authors:  Xian-Min Yu
Journal:  Mol Neurobiol       Date:  2006-02       Impact factor: 5.590

4.  Transplantation of Induced Pluripotent Stem Cell-Derived Neural Stem Cells Mediate Functional Recovery Following Thoracic Spinal Cord Injury Through Remyelination of Axons.

Authors:  Ryan P Salewski; Robert A Mitchell; Lijun Li; Carl Shen; Maria Milekovskaia; Andras Nagy; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2015-05-15       Impact factor: 6.940

Review 5.  Emerging therapies for acute traumatic spinal cord injury.

Authors:  Jefferson R Wilson; Nicole Forgione; Michael G Fehlings
Journal:  CMAJ       Date:  2012-12-10       Impact factor: 8.262

Review 6.  Emerging approaches to the surgical management of acute traumatic spinal cord injury.

Authors:  Jefferson R Wilson; Michael G Fehlings
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

7.  A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.

Authors:  Robert G Grossman; Michael G Fehlings; Ralph F Frankowski; Keith D Burau; Diana S L Chow; Charles Tator; Angela Teng; Elizabeth G Toups; James S Harrop; Bizhan Aarabi; Christopher I Shaffrey; Michele M Johnson; Susan J Harkema; Maxwell Boakye; James D Guest; Jefferson R Wilson
Journal:  J Neurotrauma       Date:  2013-10-11       Impact factor: 5.269

8.  Effectiveness of Riluzole as a pharmacotherapeutic treatment option for early cervical myelopathy: a double-blinded, placebo-controlled randomised controlled trial.

Authors:  S Rajasekaran; Siddharth N Aiyer; Ajoy Prasad Shetty; Rishi Mugesh Kanna; Anupama Maheswaran; Janardhan Yerram Shetty
Journal:  Eur Spine J       Date:  2015-11-23       Impact factor: 3.134

Review 9.  Spinal cord injury: time to move?

Authors:  Serge Rossignol; Martin Schwab; Michal Schwartz; Michael G Fehlings
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

10.  The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.

Authors:  Jennifer N Dulin; Meredith L Moore; Raymond J Grill
Journal:  J Neurotrauma       Date:  2013-01-23       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.